Survival outcomes of RASp mutations in specific clinical and genomic subsets in CMML. (A-B) Kaplan-Meier survival estimate curves for OS (A) or LFS (B) of RAS mutant (RAS^MT, n = 342) compared with RAS^WT (n = 196) CMML. Only patients with RAS^WT in whom all RAS mutant genes were sequenced are included. (C-D) Kaplan-Meier survival estimate curves for OS (C) or LFS (D) of MD-CMML or MP-CMML based on the presence or absence of RASp mutations. Only patients with RASp mutations in whom all RASp genes were sequenced are included (n = 196). (E) Kaplan-Meier survival estimate curve for LFS based on PTPN11 mutational status (mutant, PTPN11^MT; wildtype, PTPN11^WT) among MD-CMML or MP-CMML. (F-H) Kaplan-Meier survival estimate curves for LFS based on (F) RAS mutant and TET2 (mutant, TET2^MT; wildtype, TET2^WT) mutational status, (G) NRAS (mutant, NRAS^MT; wildtype, NRAS^WT) and RUNX1 (mutant, RUNX1^MT; wildtype, RUNX1^WT) mutational status, or (H) KRAS or CBL (mutant, KRAS/CBL^MT; wildtype, KRAS/CBL^WT) and IDH2 (mutant, IDH2^MT; wildtype, IDH2^WT) mutational status.